ONENESS

Corporate Presentation

16th Morgan Stanley Healthcare Conference

Sep 2018

Disclaimer

The statements and contents included in this presentation are confidential, proprietary information that are the property of ONENESS Biotech Co., Ltd..

This presentation may include statements regarding our future results of operations, performance, financial condition, development or marketing of our products or business prospects, and shall not be disclosed intentionally or publicly for any purposes without ONENESS Biotech's prior consent. ONENESS Biotech reserves the right to pursue legal action if any violation.

Highlights of Milestones

2008	• Founded with R&D focus in new drugs for unmet medical need.
2011	• Listed on Taiwan Stock Exchange (4743).
2013	• Core asset – ON101 approved by US FDA to proceed with 1^{st} Phase III MRCT Trial .
2015	• Granted SBIR sponsorship by Ministry of Economic Affairs, Taiwan.
2016	• Core asset – ON101 reached 62.7% complete healing rate based on 1^{st} Phase III MRCT Trial interim analysis.
2017	• ON101 approved by CFDA to proceed with 1^{st} Phase III MRCT Trial.
2018	• ON101 approved by US FDA to proceed with 2^{nd} Phase III MRCT Trial. • ON101 submitted to Taiwan FDA for NDA review. • Nancho plant estabilished 50mm capacity of ON101 tubes yearly .

Consolidated Balance Sheets

(Currency in thousand USD)

Item	2016/12/31	2017/12/31	2018/06/30
Current assets	52,308	41,244	32,462
Property, plant and equipment	5,825	15,190	17,503
Intangible assets	766	770	835
Other assets	26,290	26,842	28,895
Total assets	**85,189**	**84,046**	**79,696**
Total liabilities	**1,047**	**882**	**824**
Share capital	65,057	65,251	65,251
Capital surplus	25,714	25,486	20,370
Retained earnings	(475)	(5,182)	(3,126)
Other equity	(6,154)	(2,391)	(3,623)
Total equity	**84,142**	**83,164**	**78,872**

Core Asset - ON101

Globally Unmet,
We Met.

The Best-in-class for DFU

DFU (Diabetic Foot Ulcer)



>26 million DFUs worldwide

>8.5 million new ulcers every year

65% ulcers remain **unhealed** in 12 months

30-40% recurrence every year

Huge Financial Burden



Global expenditure > US$60 bn

High Mortality Rate



Nearly **50%**
mortality rate
in 5 yrs after
amputation

Every 30 secs
a limb is amputated

Up to **25% diabetes patients**
develop an ulcer
over lifetime

1st Market Launch during 2019-2020



- ✓ Phase III MRCT Trial co-developed with national diabetes KoLs
- ✓ NDA expected between 2019-2020
- ✓ Commercialization with local partner

ONENESS

Clinical Development

Completed

2016 Q3
1st Phase III interim analysis

2017 Q3
1st Phase III trial approved to proceed in China

2018 Q1
US FDA approved to proceed 2nd Phase III trial

2018 Q2
1st Phase III data submitted to Taiwan FDA for NDA review

Ongoing

2018 Q4
EU IND **Phase III** trial submission

2019-2020
Taiwan/China **NDA** approval

Achieved primary endpoint
in 1st Phase III Interim Analysis



Definite Clinical Advantages

- ✓Rapid Healing
- ✓Superior Complete Healing Rate
- ✓Consistent Efficacy
- ✓Easy Home Care, Higher Compliance
- ✓Odorless Wounds
- ✓No Safety Concern in Cancer Risk

Best compliance

Revolutionary treatment. Just use at home.

Now (w/o ON101)

Ulceration

↓

Hospital

↓

- Reduced Productivity
- Hospital resources occupied
- Plateau effect
- Surgically expensive

↓

Healed

Future (w/ ON101)

Ulceration

↓

Hospital

↓

Home care

↓

Healed

ONENESS

Preparation for Market Entry

Streamlined Control on Price

We have established

- A GACP site for mass cultivation of the raw material
- PIC/s GMP plant for global supply (capacity with 50 mn tubes in 1st stage)

44-acre GACP Cultivation Site

PIC/s GMP Plant

-confidential-

Global IP Protection



Formulation and Clinical Use
- Topical formulation
- Method of treating wounds and skin disorders

Active Ingredient Protection
- Use of flavonoid compound in preparation of composition for healing wound

Plant Extracts Protection
- Plant extracts for treating skin disorders and enhancing healing of wounds for diabetic patients

Manufacturing Process Protection
- The process for preparing active pharmaceutical composition

ONENESS

Marketing Plan

2019

- Launch in Taiwan
- Phase III trial for EU/US starts with partner

2020

- Launch in China

2021 & beyond

- US&EU Phase III trial completes
- Launch in US & EU
- Included in China National Medical Insurance
- Extend indications to more chronic wounds.

-confidential-

Breakthrough Results to be Presented

The above breakthrough findings of ON101 in treatment of DFU will be presented orally at IDF congress.

IDF
Diabetes Complications Congress 2018
Hyderabad, India - 25-27 October

Title: First new drug with over 60% complete wound closure in diabetic foot ulcers from phase III trial interim analysis report

Presenter: Jui-Ching Chen, Ph.D.

Globalization by Innovation

Contact

Zoe Chen, Business Development
Zoe.Chen@onenessbio.com.tw